Summary

The peritoneal dialysis market is projected to reach USD 12.70 Billion by 2029 from USD 9.58 Billion in 2024 at a CAGR of 5.8% during the forecast period. Favorable healthcare policies in developed markets have highly increased access to peritoneal dialysis since many now offer reimbursements for home-based dialysis treatments. In most cases, the United States, Canada, and several others in Europe have come up with policies that acknowledge the cost-effectiveness and better benefits for patients through peritoneal dialysis over in-center hemodialysis. Such policies reduce the barriers associated with the cost of treatment by establishing reimbursement coverage for a significant portion of the PD-associated treatment costs. This could make PD a much more affordable and accessible form of therapy for patients, and reimbursement programs promote the practice of healthcare providers to recommend PD due to its flexibility and practicality, also for those preferring home management of treatment. For instance, in the United States, Medicare's ESRD program encourages wider adoption by providing reimbursements for home dialysis. Likewise, other developed markets also are following and encouraging home dialysis since it reduces hospital admissions, improves patient outcomes, and reduces burdens on the healthcare facilities. The financial support that comes with PD has become a reason for the aged and bedridden patients who have been able to live better as a result of reduced immobilization and enhanced personal care.

“The peritoneal solution bags segment is accounted for the largest share of peritoneal dialysis market.”
Peritoneal dialysis solution bags are less expensive than machines because they are not reliant upon pricey technology and maintenance. Because of this, these bags are very inexpensive for patients and healthcare systems, whose production and distribution costs make it possible to sell these bags at prices within everyone's reach, especially in countries that have tightly constrained health care budgets. Solution bags also reduce the requirement for costly equipment and training of the staff, thereby reducing the overall cost of treatment. This adds to the attractiveness of solution bags as a treatment option for a larger number of patients in resource-poor settings for access to necessary dialysis.

“Continuous Ambulatory Peritoneal Dialysis (CAPD) segment holds the largest market share of peritoneal dialysis market.”
The increased coverage of CAPD supplies, especially the solution bags, has stimulated its adoption, especially in developing countries. CAPD, being any form of dialysis treatment, requires only basic supplies, like solution bags, and hence is much simpler to distribute and implement in areas with very poor healthcare resources than expensive machinery. Therefore, it is more cost-effective and accessible to patients in low-resource settings as a practically offered form of dialysis. Ease of use and minimization of the use of hospital facilities further increase the adoption rate of CAPD, thereby increasing access to dialysis care in underprivileged areas globally.

“End-stage renal disease segment holds the largest market share in the global peritoneal dialysis market and expected to grow at the highest CAGR during the forecast period”
Most healthcare systems promote home dialysis options to decrease the prevalence of hospital visits attributed to end-stage renal disease (ESRD), which subsequently saves the overall cost of healthcare. Health care providers would benefit from home peritoneal dialysis by reducing the need for in-center dialysis, thus saving hospital facility capacities and minimizing the problems it poses both to facilities and personnel. Home dialysis will also improve patients' lives as they assume control over their treatment. An added advantage of home-based PD is that it is very economical since it saves transportation costs, it minimizes the susceptibility to infection, and encourages continuity of care, which makes it an attractive modality for health care systems.

“Home care setttings segment accounted for the largest market share in the global peritoneal dialysis market and expected to grow at the highest CAGR during the forecast period.”
Portable and user-friendly dialysis equipment have further improved the safety and ease of treatment in the home setting for patients. Modern peritoneal dialysis machines are well designed with intuitive interfaces, automation, and compact size, making them devices that patients can use with relative ease, without relying so much on medical knowledge. Thus, independent and comfortable home-based dialysis has reduced a patient's dependence on healthcare professionals. Safety measures have upgraded with live monitoring and automatic alarms that enhanced outcomes best dealt with early before dangers occur. In those innovations, patient confidence in handling their care improved, while the treatment compliance was generally enhanced.

“North America to witness the substantial growth rate during the forecast period.”
The peritoneal dialysis market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries based on the region type. In 2023, the Asia Pacific region is projected to exhibit the highest CAGR during the forecast period. However, North America accounts for the largest market share of the peritoneal dialysis market in 2023. North America is the largest regional market for global peritoneal dialysis, and this is partly because healthcare providers in this region have been trained specifically to manage this treatment. This places them in a better position to ensure that patients requiring the treatment receive a holistic education on how to carry out procedures safely and effectively at home. Moreover, these professionals provide timely interventions through effective monitoring, thus making the outcomes better as well as complications as low as possible. Specialized training programs and ongoing professional development in the region further underpin quality care. Such professionalism among healthcare professionals has indeed contributed to success in the introduction and spread of peritoneal dialysis in North America.

A breakdown of the primary participants (supply-side) for the peritoneal dialysis market referred to for this report is provided below:
• By Company Type: Tier 1–45%, Tier 2–30%, and Tier 3–25%
• By Designation: C-level–35%, Director Level–25%, and Others–40%
• By Region: North America–40%, Europe–20%, Asia Pacific–25%, Latin America- 10%, and Middle East and Africa– 3% and GCC Countries– 2%
Prominent players in this market include Baxter International Inc. (US), Fresenius Medical Care AG (Germany), Medtronic plc (Ireland), Davita Inc. (US), Becton, Dickinson and Company (US), Utah Medical Products, Inc. (US), Terumo Corporation (Japan), Diaverum AB (Sweden), Medionics (Canada), Newsol Technologies (Canada), Apollo Dialysis Pvt Ltd (India), U.S. Renal Care, Inc. (US), Northwest Kidney Centers (US), Relavo (US), Mitra Industries Pvt Ltd (India), JMS Co., Ltd. (Japan), AMECATH (Egypt), Polymedicure (India), Huaren Pharmaceutical (China), AWAK Technologies (Singapore), Innovative Renal Care (US), Romsons (India), SSEM Mthembu Medical (Pty) Ltd (South Africa), Renax Biomedical Technology Co., Ltd (China), and Advin Health Care (India).
Research Coverage:
The market study covers the peritoneal dialysis market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by offering, modality, disease indication, end user and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
 Analysis of Market Dynamics: Drivers (rising prevalence of chronic kidney diseases, growing prevalence of diabetes and hypertension, and technological advancements and increased investment in R&D) restraints (underutilization of peritoneal dialysis in low-income and lower-middle-income countries (LLMICs)) opportunities (increasing growth opportunities in emerging economies, and surge in demand for home dialysis treatment), and challenges (growing incidence of treated kidney failure, and shortage of skilled nephrologists in low-income and lower-middle-income countries (LLMICs))
 Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new product launches in the peritoneal dialysis market.
 Market Development: Comprehensive information on the lucrative emerging markets, components, demographics, end-user, and region.
 Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the peritoneal dialysis market.
 Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the peritoneal dialysis market like Baxter International Inc. (US), Fresenius Medical Care AG (Germany), Medtronic plc (Ireland), Davita Inc. (US), Becton, Dickinson and Company (US).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS & EXCLUSIONS 25
1.3 STUDY SCOPE 26
1.3.1 MARKETS COVERED 26
1.3.2 YEARS CONSIDERED 27
1.4 CURRENCY CONSIDERED 27
1.5 STAKEHOLDERS 28
1.6 IMPACT OF AI/GEN AI 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
2.1.1 SECONDARY DATA 30
2.1.2 PRIMARY DATA 32
2.2 MARKET SIZE ESTIMATION 34
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 34
2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 36
2.2.3 USAGE-BASED MARKET ESTIMATION 37
2.2.4 PRIMARY RESEARCH VALIDATION 39
2.3 GROWTH FORECAST ESTIMATION 39
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 41
2.5 STUDY ASSUMPTIONS 42
2.6 RISK ASSESSMENT 42
2.7 RESEARCH LIMITATIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 48
4.1 PERITONEAL DIALYSIS MARKET OVERVIEW 48
4.2 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY OFFERING (2023) 49
4.3 PERITONEAL DIALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
4.4 REGIONAL MIX: PERITONEAL DIALYSIS MARKET (2024−2029) 51
4.5 PERITONEAL DIALYSIS MARKET: DEVELOPED VS. DEVELOPING ECONOMIES 51

5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
5.2.1 DRIVERS 53
5.2.1.1 Rising prevalence of chronic kidney diseases 53
5.2.1.2 Growing prevalence of diabetes and hypertension 54
5.2.1.3 Technological advancements and increased investment in R&D 55
5.2.2 RESTRAINTS 56
5.2.2.1 Underutilization of peritoneal dialysis in low-income and lower-middle-income countries (LLMICs) 56
5.2.3 OPPORTUNITIES 57
5.2.3.1 Increasing growth opportunities in emerging economies 57
5.2.3.2 Surge in demand for home dialysis treatment 58
5.2.4 CHALLENGES 58
5.2.4.1 Shortage of skilled nephrologists in low-income and lower-middle-income countries (LLMICs) 58
5.2.4.2 High risk of peritonitis as a barrier to peritoneal dialysis adoption 59
5.3 INDUSTRY TRENDS 59
5.3.1 INCREASED ADOPTION OF HOME-BASED TREATMENTS 59
5.3.2 RISING INCIDENCE OF CHRONIC KIDNEY DISEASE (CKD) 60
5.4 TECHNOLOGY ANALYSIS 60
5.4.1 KEY TECHNOLOGIES 60
5.4.1.1 Automated peritoneal dialysis (APD) machines 60
5.4.2 COMPLEMENTARY TECHNOLOGIES 61
5.4.2.1 Remote monitoring systems 61
5.4.3 ADJACENT TECHNOLOGIES 61
5.4.3.1 Wearable technology 61
5.5 SUPPLY CHAIN ANALYSIS 61
5.6 VALUE CHAIN ANALYSIS 63
5.7 TRADE ANALYSIS 63
5.7.1 TRADE ANALYSIS FOR PERITONEAL DIALYSIS MACHINES, SOLUTION BAGS, CATHETERS, AND TRANSFER SETS (HS CODE 9018) 63
5.8 PORTER’S FIVE FORCES ANALYSIS 65
5.8.1 THREAT OF NEW ENTRANTS 66
5.8.2 THREAT OF SUBSTITUTES 66
5.8.3 BARGAINING POWER OF SUPPLIERS 66
5.8.4 BARGAINING POWER OF BUYERS 66
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 66

5.9 REGULATORY ANALYSIS 67
5.9.1 REGULATORY LANDSCAPE 67
5.9.1.1 North America 67
5.9.1.1.1 US 67
5.9.1.1.2 Canada 67
5.9.1.2 Europe 67
5.9.1.3 Asia Pacific 68
5.9.1.3.1 India 68
5.9.1.3.2 China 68
5.9.1.3.3 Japan 68
5.9.1.3.4 South Korea 68
5.9.1.4 Latin America 69
5.9.1.4.1 Brazil 69
5.9.1.4.2 Mexico 69
5.9.1.5 Middle East 69
5.9.1.6 Africa 70
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
5.10 PATENT ANALYSIS 72
5.10.1 PATENT PUBLICATION TRENDS FOR PERITONEAL DIALYSIS MARKET 72
5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 73
5.11 PRICING ANALYSIS 74
5.11.1 AVERAGE SELLING PRICE OF PERITONEAL DIALYSIS PRODUCTS AND CONSUMABLES, BY KEY PLAYER (2023) 74
5.12 KEY CONFERENCES & EVENTS, 2024–2025 75
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 76
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 76
5.13.2 KEY BUYING CRITERIA 77
5.14 ECOSYSTEM ANALYSIS 78
5.15 ADJACENT MARKET ANALYSIS 79
5.15.1 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET 79
5.15.2 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 80
5.16 CASE STUDY ANALYSIS 81
5.17 IMPACT OF GENERATIVE AI ON PERITONEAL DIALYSIS MARKET 82
5.18 UNMET NEEDS AND END-USER EXPECTATIONS 83
5.19 TRENDS/DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESSES 84
5.20 INVESTMENT & FUNDING SCENARIO 84
5.21 PROCEDURE DATA ANALYSIS 85
5.21.1 PREVALENCE DATA FOR TREATED KIDNEY FAILURE 86

6 PERITONEAL DIALYSIS MARKET, BY OFFERING 90
6.1 INTRODUCTION 91
6.2 PERITONEAL DIALYSIS PRODUCTS 91
6.2.1 PERITONEAL DIALYSIS SOLUTION BAGS 93
6.2.1.1 High demand for solutions to boost segmental growth 93
6.2.2 PERITONEAL DIALYSIS MACHINES 95
6.2.2.1 Rising prevalence of chronic diseases in emerging economies to boost adoption 95
6.2.3 PERITONEAL DIALYSIS CATHETERS 97
6.2.3.1 Favorable reimbursement policies to support market growth 97
6.2.4 PERITONEAL DIALYSIS TRANSFER SETS 98
6.2.4.1 Product recalls to limit market growth 98
6.2.5 OTHER PERITONEAL DIALYSIS PRODUCTS 99
6.3 PERITONEAL DIALYSIS SERVICES 100
6.3.1 BETTER PRIVACY AND INCREASED COMFORT OF AT-HOME DIALYSIS TREATMENT TO DRIVE MARKET 100
7 PERITONEAL DIALYSIS MARKET, BY MODALITY 102
7.1 INTRODUCTION 103
7.2 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD) 103
7.2.1 SUPERIOR CLEARANCE OF HIGH-MOLECULAR-WEIGHT SUBSTANCES TO DRIVE MARKET 103
7.3 AUTOMATED PERITONEAL DIALYSIS (APD) 104
7.3.1 RISK OF RAPID DECLINE IN RESIDUAL RENAL FUNCTIONS TO LIMIT ADOPTION 104
8 PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION 106
8.1 INTRODUCTION 107
8.2 END-STAGE RENAL DISEASE 107
8.2.1 GROWING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET 107
8.3 ACUTE KIDNEY INJURY 108
8.3.1 INCREASING HOSPITALIZATIONS TO PROPEL MARKET GROWTH 108
8.4 OTHER DISEASES 110
9 PERITONEAL DIALYSIS MARKET, BY END USER 111
9.1 INTRODUCTION 112
9.2 HOME CARE SETTINGS 112
9.2.1 LOWER COST AND SHORTER HOSPITAL STAYS TO AID MARKET GROWTH 112
9.3 HOSPITALS & INDEPENDENT DIALYSIS CENTERS 113
9.3.1 IMPROVED FACILITIES AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET 113
9.4 OTHER END USERS 115
10 PERITONEAL DIALYSIS MARKET, BY REGION 117
10.1 INTRODUCTION 118
10.1.1 PERITONEAL DIALYSIS PREVALENCE DATA 118
10.1.2 PERITONEAL DIALYSIS PROCEDURE DATA 119
10.2 NORTH AMERICA 121
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 121
10.2.2 US 125
10.2.2.1 US to account for largest market share during study period 125
10.2.3 CANADA 128
10.2.3.1 Shortage of dialysis facilities and increased treatment cost
to limit market 128
10.3 EUROPE 130
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 131
10.3.2 GERMANY 133
10.3.2.1 Rising number of end-stage renal disease (ESRD) patients to boost market growth 133
10.3.3 UK 136
10.3.3.1 Increased number of new dialysis centers and technological advancements to support market growth 136
10.3.4 FRANCE 138
10.3.4.1 Low cost of peritoneal dialysis and consistent reimbursement policies to drive market growth 138
10.3.5 ITALY 141
10.3.5.1 Increasing research activities and growing patient population with acute renal failure to augment market growth 141
10.3.6 SPAIN 143
10.3.6.1 Favorable reimbursement scenario to boost market growth 143
10.3.7 REST OF EUROPE 146
10.4 ASIA PACIFIC 148
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 148
10.4.2 JAPAN 153
10.4.2.1 High prevalence of end-stage renal disease (ESRD) and large geriatric population to support market growth 153
10.4.3 CHINA 157
10.4.3.1 Increasing prevalence of diabetes and hypertension to drive market 157
10.4.4 INDIA 159
10.4.4.1 Favorable government initiatives and high prevalence of kidney disease to fuel market growth 159
10.4.5 AUSTRALIA 162
10.4.5.1 Increasing government initiatives about renal care to support market growth 162

10.4.6 SOUTH KOREA 164
10.4.6.1 Growing geriatric population with chronic kidney disease to propel market growth 164
10.4.7 REST OF ASIA PACIFIC 167
10.5 LATIN AMERICA 169
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 169
10.5.2 BRAZIL 172
10.5.2.1 Brazil to account for largest share of Latin American market during forecast period 172
10.5.3 MEXICO 174
10.5.3.1 Increasing patient population and growing middle class population to boost market growth 174
10.5.4 REST OF LATIN AMERICA 176
10.6 MIDDLE EAST & AFRICA 178
10.6.1 GROWING DEMAND FOR CONVENIENT AND ACCESSIBLE RENAL CARE TO PROPEL GROWTH 178
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 179
10.7 GCC COUNTRIES 182
10.7.1 HIGHER DISPOSABLE INCOME AND INCREASED GOVERNMENT HEALTHCARE EXPENDITURE TO PROPEL MARKET GROWTH 182
10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 182
11 COMPETITIVE LANDSCAPE 185
11.1 OVERVIEW 185
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 185
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PERITONEAL DIALYSIS MARKET 186
11.3 REVENUE ANALYSIS, 2019–2023 187
11.4 MARKET SHARE ANALYSIS, 2023 188
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 190
11.5.1 STARS 190
11.5.2 EMERGING LEADERS 191
11.5.3 PERVASIVE PLAYERS 191
11.5.4 PARTICIPANTS 191
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 192
11.5.5.1 Company footprint 192
11.5.5.2 Offering footprint 193
11.5.5.3 Modality footprint 194
11.5.5.4 Disease indication footprint 195
11.5.5.5 End-user footprint 196
11.5.5.6 Region footprint 197

11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023 197
11.6.1 PROGRESSIVE COMPANIES 197
11.6.2 RESPONSIVE COMPANIES 198
11.6.3 DYNAMIC COMPANIES 198
11.6.4 STARTING BLOCKS 198
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 199
11.7 COMPANY VALUATION & FINANCIAL METRICS 200
11.8 COMPETITIVE SCENARIO 201
11.8.1 PRODUCT APPROVALS 201
11.8.2 DEALS 201
11.8.3 EXPANSIONS 202
11.9 BRAND/PRODUCT COMPARISON 203
11.10 PERITONEAL DIALYSIS MARKET: R&D EXPENDITURE 204
12 COMPANY PROFILES 205
12.1 KEY PLAYERS 205
12.1.1 FRESENIUS MEDICAL CARE AG 205
12.1.1.1 Business overview 205
12.1.1.2 Products & services offered 206
12.1.1.3 Recent developments 208
12.1.1.3.1 Deals 208
12.1.1.4 MnM view 208
12.1.1.4.1 Right to win 208
12.1.1.4.2 Strategic choices 208
12.1.1.4.3 Weaknesses & competitive threats 208
12.1.2 BAXTER INTERNATIONAL INC. 209
12.1.2.1 Business overview 209
12.1.2.2 Products & services offered 211
12.1.2.3 Recent developments 212
12.1.2.3.1 Deals 212
12.1.2.4 MnM view 212
12.1.2.4.1 Right to win 212
12.1.2.4.2 Strategic choices 212
12.1.2.4.3 Weaknesses & competitive threats 212
12.1.3 MEDTRONIC PLC 213
12.1.3.1 Business overview 213
12.1.3.2 Products & services offered 215
12.1.3.3 Recent developments 215
12.1.3.3.1 Deals 215

12.1.3.4 MnM view 216
12.1.3.4.1 Right to win 216
12.1.3.4.2 Strategic choices 216
12.1.3.4.3 Weaknesses & competitive threats 216
12.1.4 DAVITA INC. 217
12.1.4.1 Business overview 217
12.1.4.2 Products & services offered 218
12.1.4.3 Recent developments 218
12.1.4.3.1 Deals 218
12.1.4.3.2 Expansions 218
12.1.4.4 MnM view 219
12.1.4.4.1 Right to win 219
12.1.4.4.2 Strategic choices 219
12.1.4.4.3 Weaknesses & competitive threats 219
12.1.5 BECTON, DICKINSON AND COMPANY 220
12.1.5.1 Business overview 220
12.1.5.2 Products & services offered 222
12.1.5.3 Recent developments 222
12.1.5.3.1 Expansions 222
12.1.5.4 MnM view 223
12.1.5.4.1 Right to win 223
12.1.5.4.2 Strategic choices 223
12.1.5.4.3 Weaknesses & competitive threats 223
12.1.6 TERUMO CORPORATION 224
12.1.6.1 Business overview 224
12.1.6.2 Products & services offered 225
12.1.6.3 Recent developments 225
12.1.6.3.1 Product approvals 225
12.1.6.3.2 Deals 226
12.1.6.3.3 Expansions 226
12.1.7 UTAH MEDICAL PRODUCTS, INC. 227
12.1.7.1 Business overview 227
12.1.7.2 Products & services offered 229
12.1.8 DIAVERUM AB 230
12.1.8.1 Business overview 230
12.1.8.2 Products & services offered 230
12.1.9 MEDIONICS 231
12.1.9.1 Business overview 231
12.1.9.2 Products & services offered 231

12.1.10 NEWSOL TECHNOLOGIES INC. 233
12.1.10.1 Business overview 233
12.1.10.2 Products & services offered 233
12.1.11 APOLLO DIALYSIS PVT. LTD. 234
12.1.11.1 Business overview 234
12.1.11.2 Products & services offered 234
12.1.12 U.S. RENAL CARE, INC. 235
12.1.12.1 Business overview 235
12.1.12.2 Products & services offered 235
12.1.13 NORTHWEST KIDNEY CENTERS 236
12.1.13.1 Business overview 236
12.1.13.2 Products & services offered 236
12.1.13.3 Recent developments 237
12.1.13.3.1 Deals 237
12.1.13.3.2 Expansions 237
12.1.14 RELAVO 238
12.1.14.1 Business overview 238
12.1.14.2 Products & services offered 238
12.1.15 MITRA INDUSTRIES PVT. LTD. 239
12.1.15.1 Business overview 239
12.1.15.2 Products & services offered 240
12.2 OTHER PLAYERS 241
12.2.1 JMS CO., LTD. 241
12.2.2 AMECATH 241
12.2.3 POLYMEDICURE 242
12.2.4 HUAREN PHARMACEUTICAL 242
12.2.5 AWAK TECHNOLOGIES 243
12.2.6 INNOVATIVE RENAL CARE 243
12.2.7 ROMSONS 244
12.2.8 SSEM MTHEMBU MEDICAL (PTY) LTD. 244
12.2.9 RENAX BIOMEDICAL TECHNOLOGY CO., LTD. 245
12.2.10 ADVIN HEALTH CARE 245
13 APPENDIX 246
13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 249
13.2 CUSTOMIZATION OPTIONS 251
13.3 RELATED REPORTS 251
13.4 AUTHOR DETAILS 252